Atomo Diagnostics's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 106.72.
Atomo Diagnostics's Days Inventory for the
six
months ended in Dec. 2025 was 221.72.
Atomo Diagnostics's Days Payable for the
six
months ended in Dec. 2025 was 96.63.
Therefore, Atomo Diagnostics's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 231.81.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Atomo Diagnostics Cash Conversion Cycle Related Terms
Atomo Diagnostics Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Atomo Diagnostics's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AT1 vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Atomo Diagnostics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atomo Diagnostics Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Atomo Diagnostics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Atomo Diagnostics's Cash Conversion Cycle for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atomo Diagnostics (ASX:AT1) has a Cash Conversion Cycle of 231.81 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Atomo Diagnostics and its competitors.
Is Atomo Diagnostics' Cash Conversion Cycle too high?
Atomo Diagnostics' current Cash Conversion Cycle is 231.81. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.39. Atomo Diagnostics' value of 231.81 is 48.2% above this industry median.
How does Atomo Diagnostics' Cash Conversion Cycle compare to ABT and SYK?
Atomo Diagnostics' Cash Conversion Cycle of 231.81 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.39. Atomo Diagnostics' value of 231.81 is 48.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.39, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atomo Diagnostics's current Cash Conversion Cycle of 231.81 is 48.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Atomo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atomo Diagnostics's current Cash Conversion Cycle is 231.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current Cash Conversion Cycle is 231.81 and 48.2% above the Medical Devices & Instruments industry median of 156.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current Cash Conversion Cycle is 231.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AT1 has been successfully added to your 